Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?

Abstract Background The prognosis of patients with NSCLC harboring oncogenic driver gene alterations, such as EGFR gene mutations or ALK fusion, has improved dramatically with the advent of corresponding molecularly targeted drugs. As patients were followed up for about five years in most clinical t...

Full description

Bibliographic Details
Main Authors: Shoko Sonobe Shimamura, Takehito Shukuya, Tetsuhiko Asao, Daisuke Hayakawa, Kana Kurokawa, Shiting Xu, Keita Miura, Yoichiro Mitsuishi, Ken Tajima, Rina Shibayama, Naoko Shimada, Fumiyuki Takahashi, Kazuhisa Takahashi
Format: Article
Language:English
Published: BMC 2022-03-01
Series:BMC Cancer
Subjects:
EGFR mutation
ALK rearrangement
NSCLC
Long survival
Online Access:https://doi.org/10.1186/s12885-022-09421-7

Internet

https://doi.org/10.1186/s12885-022-09421-7

Similar Items